Cocrystal Pharma Inc.

1.33+0.0076+0.58%Vol 361.51K1Y Perf 69.25%
Apr 13th, 2021 15:21 DELAYED
BID1.32 ASK1.33
Open1.30 Previous Close1.32
Pre-Market- After-Market-
 - -%  - -
Target Price
4.75 
Analyst Rating
— — 0.00
Potential %
257.17 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.41
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     61.17
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap94.88M 
Earnings Rating
Neutral
Price Range Ratio 52W %
24.89 
Earnings Date
13th May 2021

Today's Price Range

1.271.34

52W Range

0.76003.04

5 Year PE Ratio Range

-50.30-2.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-3.65%
1 Month
-16.46%
3 Months
-11.41%
6 Months
35.41%
1 Year
69.25%
3 Years
-71.86%
5 Years
-93.76%
10 Years
-

TickerPriceChg.Chg.%
COCP1.330.00760.58
AAPL134.443.20002.44
GOOG2 275.6920.90000.93
MSFT258.512.60001.02
XOM55.780.28000.50
WFC39.88-0.8900-2.18
JNJ159.87-1.7700-1.10
FB311.35-0.1900-0.06
GE13.50-0.0900-0.66
JPM154.79-1.1600-0.74
Financial StrengthValueIndustryS&P 500US Markets
24.70
25.00
0.01
0.01
-1 205.00
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 937.60
-2 921.00
-
-5.26
RevenueValueIndustryS&P 500US Markets
1.55M
0.02
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020--0.01-
Q03 2020-0.05-0.050.00
Q02 2020-0.04-0.07-75.00
Q01 2020--0.05-
Q03 2019--0.06-
Q02 2019--0.05-
Q01 2019-0.10-
Q03 2018--0.06-
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.040.00-
6/2021 QR-0.040.00-
12/2021 FY-0.170.00-
12/2022 FY-0.110.00-
Next Report Date13th May 2021
Estimated EPS Next Report-0.04
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume361.51K
Shares Outstanding71.47M
Trades Count1.12K
Dollar Volume2.21M
Avg. Volume2.68M
Avg. Weekly Volume2.22M
Avg. Monthly Volume1.24M
Avg. Quarterly Volume2.83M

Cocrystal Pharma Inc. (NASDAQ: COCP) stock closed at 1.32 per share at the end of the most recent trading day (a -6.38% change compared to the prior day closing price) with a volume of 705.20K shares and market capitalization of 94.88M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 11 people. Cocrystal Pharma Inc. CEO is Gary L. Wilcox.

The one-year performance of Cocrystal Pharma Inc. stock is 69.25%, while year-to-date (YTD) performance is -2.94%. COCP stock has a five-year performance of -93.76%. Its 52-week range is between 0.76 and 3.04, which gives COCP stock a 52-week price range ratio of 24.89%

Cocrystal Pharma Inc. currently has a PE ratio of -8.20, a price-to-book (PB) ratio of 2.01, a price-to-sale (PS) ratio of 60.75, a price to cashflow ratio of 54.20, a PEG ratio of 2.32, a ROA of -22.62%, a ROC of -91.42% and a ROE of -23.97%. The company’s profit margin is -5.26%, its EBITDA margin is -2 921.00%, and its revenue ttm is $1.55 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from Cocrystal Pharma Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Cocrystal Pharma Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Cocrystal Pharma Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Cocrystal Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cocrystal Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cocrystal Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 25.98, ATR14 : 0.18, CCI20 : -94.03, Chaikin Money Flow : -0.16, MACD : -0.12, Money Flow Index : 56.19, ROC : -5.04, RSI : 39.30, STOCH (14,3) : 12.39, STOCH RSI : 0.66, UO : 41.60, Williams %R : -87.61), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cocrystal Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

CEO: Gary L. Wilcox

Telephone: +1 786 459-1831

Address: 19805 North Creek Parkway, Bothell 98011, WA, US

Number of employees: 11

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

83%17%

Bearish Bullish

47%53%

Bearish Bullish

53%47%

News

Stocktwits